- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03731260
(PIONEER) Undersøgelse til evaluering af effektivitet og sikkerhed af avapritinib (BLU-285), en selektiv KIT-mutationsmålrettet tyrosinkinasehæmmer, versus placebo hos patienter med indolent systemisk mastocytose
Et 3-delt, randomiseret, dobbeltblindt, placebokontrolleret fase 2-studie til evaluering af sikkerhed og effektivitet af avapritinib (BLU-285), en selektiv KIT-mutationsmålrettet tyrosinkinasehæmmer, i indolent og ulmende systemisk mastocytose med symptomer, der er kontrolleret utilstrækkelig Med standard terapi
This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Edegem, Belgien, 2650
- University Hospital Antwerp
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Tom Baker Cancer Centre
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
-
-
-
Odense, Danmark, DK-5000
- Odense Universitetshospital, ORCA/Allergicentret, Hudafdeling I og Allergicenter
-
-
-
-
-
Glasgow, Det Forenede Kongerige, G12 OXL
- NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre
-
London, Det Forenede Kongerige, SE1 9RT
- Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
-
Metropolitan Borough of Wirral, Det Forenede Kongerige, CH63 4JY
- Clatterbridge Cancer Centre NHS Foundation Trust
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85054
- Mayo Clinic Hospital
-
-
California
-
Stanford, California, Forenede Stater, 94305
- Stanford Cancer Institute
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32224
- Mayo Clinic Florida
-
Tampa, Florida, Forenede Stater, 33612
- H. Lee Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Winship Cancer Institute, Emory University
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rush University Medical Center
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- University of Kansas Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Dana Farber Cancer Institute
-
Boston, Massachusetts, Forenede Stater, 02115
- Brigham & Women's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Michigan Medicine, University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Herbert Irving Comprehensive Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
- Duke University Health System (DUHS)
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- University Hospitals Cleveland Medical Center
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- University of Texas, MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Huntsman Cancer Institute
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23298
- Virginia Commonwealth University Medical Center
-
-
-
-
-
Marseille, Frankrig, 13385
- Hôpital de la Timone, Service de dermatologie
-
Paris, Frankrig, 75013
- Hôpital Pitié-Salpêtrière, Service de Dermatologie
-
Toulouse, Frankrig, 31059
- CHU Toulouse Larrey, CEREMAST, Service de Dermatologie et Allergologie cutanée
-
-
-
-
-
Groningen, Holland, 9713 GZ
- University Medical Center Groningen (UMCG)
-
Rotterdam, Holland, 3015 GD
- Erasmus Medical Center
-
-
-
-
-
Bologna, Italien, 40138
- A.O.U di Bologna - IRCCS, Istituto di Ematologia Lorenzo e Ariosto Seragnoli, Ematologia
-
Milan, Italien, 20122
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Poloclinico, UOC Ematologia
-
Salerno, Italien, 84131
- A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno
-
Verona, Italien, 37126
- Azienda Ospedaliera Universitaria Integrata di Verona
-
-
-
-
-
Oslo, Norge, 0372
- Oslo Universitetssykehus, Rikshospitalet, Department of Hematology
-
-
-
-
-
Basel, Schweiz, 4031
- University Hospital Basel
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitari Vall d'Hebron
-
Toledo, Spanien, 45071
- lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo
-
-
-
-
-
Stockholm, Sverige, 141 86
- Karolinska University Hospital, Hematologimottagningen R51
-
Uppsala, Sverige, 751 85
- Akademiska sjukhuset, Hematologmottagningen/101A
-
-
-
-
-
Aachen, Tyskland, 52074
- Uniklinik RWTH Aachen
-
Berlin, Tyskland, 10117
- Charité Universitätsmedizin Berlin
-
Hamburg, Tyskland, 20246
- University Clinic Hamburg Eppendorf, University Cancer Center Hamburg (UCCH)
-
Lübeck, Tyskland, 23538
- Universitätsklinikum Schleswig-Holstein, Hämatologie/Onkologie
-
Mainz, Tyskland, 55131
- Universitätsklinik Mainz, Universitäts-Hautklinik, Clinical Research Center
-
Mannheim, Tyskland, 68167
- Universitätsmedizin Mannheim, III. Medizinische Klinik
-
Munich, Tyskland, 80802
- Klinikum rechts der Isar, Technische Universität München
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- 1. Patient must have SM, confirmed by Central Pathology Review of BM biopsy, and central review of B- and C-findings by WHO diagnostic criteria.
- 2. Patient must have moderate-to-severe symptoms based on minimum mean total symptom score (TSS) of the ISM Symptom Assessment Form (ISM-SAF) over the 14-day eligibility screening period.
- 3. Patient must have failed to achieve adequate symptom control for 1 or more Baseline symptoms.
- 4. For patients receiving corticosteroids, the dose must be ≤ 20 mg/d prednisone or equivalent, and the dose must be stable for ≥ 14 days.
- 5. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.
Key Exclusion Criteria:
- 1. Patient has been diagnosed with any of the following WHO SM subclassifications: cutaneous mastocytosis only, smoldering SM, SM with associated hematologic neoplasm, aggressive SM, mast cell leukemia, or mast cell sarcoma.
- 2. Patient must not have received prior treatment with avapritinib.
- 3. Patient must not have had any cytoreductive therapy including but not limited to masitinib and midostaurin, or investigational agent for < 14 days or 5 half-lives of the drug (whichever is longer), and for cladribine, interferon alpha, pegylated interferon, or antibody therapy < 28 days or 5 half-lives of the drug (whichever is longer), before beginning the 14-day ISM-SAF eligibility TSS assessment.
- 4. Patient must not have received radiotherapy or psoralen and ultraviolet A (PUVA) therapy < 14 days before beginning the 14-day ISM-SAF eligibility TSS assessment.
- 5. Patient must not have received any hematopoietic growth factor the preceding 14 days before beginning the 14-day ISM-SAF eligibility TSS assessment.
- 6. Patient must not have a QT interval corrected using Fridericia's formula (QTcF) of > 480 msec.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: (Part 1) Avapritinib Dose 1 + BSC
Avapritinib will be administered orally in continuous 28-day cycles |
Avapritinib tablet
Andre navne:
|
|
Eksperimentel: (Part 1) Avapritinib Dose 2 + BSC
Avapritinib will be administered orally in continuous 28-day cycles |
Avapritinib tablet
Andre navne:
|
|
Eksperimentel: (Part 1) Avapritinib Dose 3 + BSC
Avapritinib will be administered orally in continuous 28-day cycles |
Avapritinib tablet
Andre navne:
|
|
Placebo komparator: (Part 1) Placebo + BSC
Placebo will be administered orally in continuous 28-day cycles |
Placebo tablet |
|
Eksperimentel: (Part 2) Avapritinib RP2D + BSC
Avapritinib will be administered orally in continuous 28-day cycles |
Avapritinib tablet
Andre navne:
|
|
Placebo komparator: (Part 2) Placebo + BSC
Placebo will be administered orally in continuous 28-day cycles |
Placebo tablet |
|
Eksperimentel: (Part 3) Avapritinib RP2D + BSC
Avapritinib will be administered orally in continuous 28-day cycles |
Avapritinib tablet
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Del 1: Anbefalet fase 2-dosis (RP2D) til patienter med ISM
Tidsramme: 9 måneder
|
9 måneder
|
|
|
Del 3: Antal deltagere med uønskede hændelser
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
Part 2: Mean change in ISM Symptom Assessment Form (ISM-SAF) total symptom score (TSS) as compared to placebo
Tidsramme: 6 months
|
0 - 110 points (higher value represents worse symptom outcomes) |
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Del 2: Andel af patienter med ≥50 % reduktion i serumtryptase
Tidsramme: 6 måneder
|
6 måneder
|
|
|
Del 2: Andel af patienter med en ≥50 % reduktion i perifert blod V-kit Hardy-Zuckerman 4 feline sarkom viral onkogen homolog aspartat 816 valin (KIT D816V) allelfraktion eller upåviselig for patienter med påviselig mutation ved baseline
Tidsramme: 6 måneder
|
6 måneder
|
|
|
Del 2: Andel af patienter med ≥50 % reduktion i ISM-SAF TSS
Tidsramme: 6 måneder
|
6 måneder
|
|
|
Del 2: Andel af patienter med ≥30 % reduktion i ISM-SAF TSS
Tidsramme: 6 måneder
|
6 måneder
|
|
|
Del 2: Andel af patienter med en ≥50 % reduktion i knoglemarvsmastceller eller ingen aggregater for patienter med aggregater ved baseline
Tidsramme: 6 måneder
|
6 måneder
|
|
|
Del 1, 2 og 3: Ændring i serumtryptase
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
Del 1, 2 og 3: Ændring i KIT D816V allelbyrde i blod
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
Del 1, 2 og 3: Ændring i knoglemarvsmastceller
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
Del 1, 2 og 3: Ændring i samtidig brug af bedste støttende pleje (BSC)
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
Del 1, 2 og 3: Ændring fra baseline i ISM-SAF-score
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
Del 1, 2 og 3: Ændring i Mastocytose Quality of Life Questionnaire (MC-QoL)
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
Del 1, 2 og 3: Ændring i patientens globale indtryk af symptomsværhedsgrad (PGIS)
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
Parts 1, 2, and 3: Change in 12-item Short Form Health Survey (SF-12)
Tidsramme: Up to 5 years
|
0 - 100 points (higher value represents better symptom outcomes) |
Up to 5 years
|
|
Parts 1, 2, and 3: Change in Patients' Global Impression of Change (PGIC)
Tidsramme: Up to 5 years
|
1 - 7 (higher value represents worse symptom outcomes) |
Up to 5 years
|
|
Parts 1, 2, and 3: Change in EuroQuol 5 Dimensions 5 Levels (EQ 5D-5L)
Tidsramme: Up to 5 years
|
0 - 100 (higher value represents better symptom outcomes) |
Up to 5 years
|
|
Parts 1, 2, and 3: Safety of avapritinib as assessed by number of adverse events
Tidsramme: Up to 5 years
|
CTCAE version 5.0 |
Up to 5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Padilla B, Shields AL, Taylor F, Li X, Mcdonald J, Green T, Boral AL, Lin HM, Akin C, Siebenhaar F, Mar B. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study. Orphanet J Rare Dis. 2021 Oct 18;16(1):434. doi: 10.1186/s13023-021-02037-3.
- Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M. Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid. 2023 Jun;2(6):EVIDoa2200339. doi: 10.1056/EVIDoa2200339. Epub 2023 May 23.
- Siebenhaar F, Broesby-Olsen S, Castells M, George TI, Livideanu CB, Alvarez-Twose I, Panse J, Barete S, Reiter A, Dybedal I, Akin C, Van Daele P, Radia DH, Cerquozzi S, Ustun C, Sabato V, Gotlib J, Rafferty M, DeAngelo DJ, Schafhausen P, Ungerstedt J, Ogbogu PU, Florell S, Wada DA, Rets A, Lin HM, Bidollari I, Hong J, Shaheen D, Lampson B, Hartmann K. Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study. J Am Acad Dermatol. 2026 Jun;94(6):1705-1713. doi: 10.1016/j.jaad.2026.02.025. Epub 2026 Feb 12.
- Worth S, George TI, Shaheen DJ, Roche M, Vachhani P. Chronic Anaphylaxis With Indolent Systemic Mastocytosis: A Case Report. Case Rep Hematol. 2025 Nov 6;2025:9562195. doi: 10.1155/crh/9562195. eCollection 2025.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- BLU-285-2203
- 2018 (U.S. NIH-bevilling/kontrakt)
- 2018-000588-99 (EudraCT nummer)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .